10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Kallikrein 13 Antibody (C-term) Blocking peptide
Synthetic peptide
Catalog # BP6332b

Specification

Kallikrein 13 Antibody (C-term) Blocking peptide - Product Information

Primary Accession Q9UKR3

Kallikrein 13 Antibody (C-term) Blocking peptide - Additional Information

Gene ID 26085

Other Names
Kallikrein-13, 3421-, Kallikrein-like protein 4, KLK-L4, KLK13, KLKL4

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP6332b was selected from the C-term region of human KLK13. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

Kallikrein 13 Antibody (C-term) Blocking peptide - Protein Information

Name KLK13

Synonyms KLKL4

Cellular Location
Secreted.

Tissue Location
Expressed in prostate, breast, testis and salivary gland

Kallikrein 13 Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

Kallikrein 13 Antibody (C-term) Blocking peptide - Images

Kallikrein 13 Antibody (C-term) Blocking peptide - Background

Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. Expression of KLK13 is regulated by steroid hormones and may be useful as a marker for breast cancer.

Kallikrein 13 Antibody (C-term) Blocking peptide - References

Kapadia, C., et al., Biochem. Biophys. Res. Commun. 323(3):1084-1090 (2004).Petraki, C.D., et al., Prostate Cancer Prostatic Dis. 6(3):223-227 (2003).Chang, A., et al., Br. J. Cancer 86(9):1457-1464 (2002).Chang, A., et al., Anticancer Res. 21(5):3147-3152 (2001).Diamandis, E.P., et al., Trends Endocrinol. Metab. 11(2):54-60 (2000).